Logo

Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replica… read more

Healthcare

Biotechnology

19 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$4.34

Price

-1.59%

-$0.07

Market Cap

$857.314m

Small

Price/Earnings

5.2x

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-1457.1%

EBITDA Margin

-1463.5%

Net Profit Margin

-1099.6%

Free Cash Flow Margin

-1457.1%

EBITDA Margin

-1463.5%

Net Profit Margin

-1099.6%

Free Cash Flow Margin
Revenue

$191.445m

+136.7%

1y CAGR

+5.7%

3y CAGR

+68.1%

5y CAGR
Earnings

$160.720m

+39.5%

1y CAGR

+12.9%

3y CAGR

+11.9%

5y CAGR
EPS

$0.82

+42.1%

1y CAGR

+20.0%

3y CAGR

+24.3%

5y CAGR
Book Value

$260.177m

$277.164m

Assets

$16.987m

Liabilities

$3.909m

Debt
Debt to Assets

1.4%

-

Debt to EBITDA
Free Cash Flow

-$34.356m

+30.3%

1y CAGR

-29.0%

3y CAGR

-9.9%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases